Evidence map›Paper›PMID 39878099›Full record

Trial reportAnti-cancer drugs2025

A phase II study of anlotinib as first-line maintenance therapy for advanced ovarian cancer.

Siyuan Li, Yanqin Zhang, Rong Yang, Qingfan Yang, Shuangyan Han, Dan Li, Zhenhua Zhang, Qinglian Wen

Abstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Anti-cancer drugs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Siyuan LiOncology Department, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan Province.
Yanqin ZhangOncology Department, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan Province.
Rong YangOncology Department, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan Province.
Qingfan YangOncology Department, Chongqing University Affiliated Renji Hospital, Chongqing.
Shuangyan HanOncology Department, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan Province.
Dan LiOncology Department, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan Province.
Zhenhua ZhangOncology Department, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan Province.
Qinglian WenOncology Department, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan Province.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anlotinib, a tyrosine kinase inhibitor, has shown encouraging antitumor activity in platinum-resistant/refractory ovarian cancer. The efficacy of anlotinib as maintenance therapy in advanced ovarian cancer remains unclear. Therefore, we designed this study to evaluate the efficacy and safety of anlotinib maintenance therapy following first-line treatment with paclitaxel and platinum-based chemotherapy in advanced ovarian cancer. In this single-arm, phase II clinical trial, patients with newly diagnosed advanced ovarian cancer were received anlotinib monotherapy as maintenance therapy once after a response to platinum-based chemotherapy until tumor progression or intolerable toxicity. The primary endpoint was progression-free survival. From April 2020 to June 2021, 24 patients were enrolled in this study. The median follow-up was 40.17 months (interquartile range, 32.40-47.93 months). Of 21 patients with efficacy value, the median progression-free survival and median overall survival were 15.8 months (95% confidence interval, 6.8-24.8 months) and 43.8 months (95% confidence interval, 25.45-62.15 months). The quality-adjusted progression-free survival was 14.4 months and there were no observed treatment-related deaths or serious treatment-emergent adverse events, demonstrating the safety of anlotinib in maintenance therapy. Anlotinib shows significant potential as a first-line maintenance therapy for advanced ovarian cancer, extending survival and providing a reliable treatment option.

Indexed as

Antineoplastic AgentsIndolesOvarian NeoplasmsProtein Kinase InhibitorsQuinolinesAdultAgedFemaleHumansMaintenance ChemotherapyMiddle AgedProgression-Free SurvivalanlotinibAntineoplastic AgentsIndolesProtein Kinase InhibitorsQuinolinesanlotinibovarian cancerphase II studytargeted therapytyrosine kinase inhibitor

Identifiers

PMID39878099
PMCPMC11969364

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.